Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients

This study aimed to describe the pharmacokinetics of midazolam and its cytochrome P450 3A (CYP3A) mediated metabolite 1‐OH‐midazolam in morbidly obese patients receiving oral and i.v. midazolam before (n = 20) and one year after weight loss surgery (n = 18), thereby providing insight into the influe...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:CPT Pharmacometrics Syst Pharmacol
Autori principali: Brill, MJE, Välitalo, PAJ, Darwich, AS, van Ramshorst, B, van Dongen, HPA, Rostami–Hodjegan, A, Danhof, M, Knibbe, CAJ
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2015
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4728292/
https://ncbi.nlm.nih.gov/pubmed/26844012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12048
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi